At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 434 enrolled
Drug / intervention
S6G5T-3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating S6G5T-3 and S6G5T-8 for Acne Vulgaris. Completed, enrolled 434 participants across 1 site.
Detailed Summary
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartDec 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedDec 3, 2018
Enrollment StartDec 14, 2018
Primary CompletionOct 23, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.6 years ago
Interventions
S6G5T-3drug
Once a day topical cream
S6G5T-8drug
Once a day topical cream